Production (Stage)
Celldex Therapeutics, Inc.
CLDX
$20.34
-$0.92-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 24.49% | 1.99% | 128.55% | 155.05% | 92.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.49% | 1.99% | 128.55% | 155.05% | 92.76% |
| Cost of Revenue | 50.16% | 38.59% | 33.08% | 39.77% | 33.56% |
| Gross Profit | -51.49% | -40.86% | -29.16% | -35.79% | -31.46% |
| SG&A Expenses | 20.64% | 24.69% | 29.41% | 30.73% | 23.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.85% | 35.70% | 32.33% | 37.81% | 31.39% |
| Operating Income | -44.63% | -37.34% | -29.21% | -34.67% | -29.72% |
| Income Before Tax | -23.45% | -11.62% | -23.65% | -32.78% | -22.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.45% | -11.62% | -23.65% | -32.78% | -22.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.45% | -11.62% | -23.65% | -32.78% | -22.12% |
| EBIT | -44.63% | -37.34% | -29.21% | -34.67% | -29.72% |
| EBITDA | -45.42% | -38.02% | -29.71% | -35.26% | -30.24% |
| EPS Basic | 5.14% | 15.95% | 2.69% | -14.24% | -12.67% |
| Normalized Basic EPS | -3.61% | 8.39% | 11.79% | -4.24% | -11.34% |
| EPS Diluted | 5.29% | 16.08% | 3.00% | -13.84% | -12.67% |
| Normalized Diluted EPS | -3.61% | 8.39% | 11.79% | -4.24% | -11.34% |
| Average Basic Shares Outstanding | 29.03% | 32.92% | 28.78% | 18.92% | 9.25% |
| Average Diluted Shares Outstanding | 29.03% | 32.92% | 28.78% | 18.92% | 9.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |